Stocks On the Move: Apricus Biosciences Inc, Jazz Pharmaceuticals plc, and Cameco Corp

U.S. stocks are sitting in the red, with Fed Chair Janet Yellen scheduled to step up to the mic shortly. Among specific equities in focus today are drug stocks Apricus Biosciences Inc (NASDAQ:APRI) and Jazz Pharmaceuticals plc - Ordinary Shares (NASDAQ:JAZZ), as well as uranium producer Cameco Corp (USA) (NYSE:CCJ). Here's a quick look at what's moving APRI, JAZZ, and CCJ.

• APRI has soared over 133% to trade at $3.52 -- making it the top percentage gainer on the Nasdaq -- after the drugmaker's erectile dysfunction treatment Vitaros was approved in Mexico. This is a dramatic turn of events for the stock, which had lost nearly nine-tenths of its value year-over-year heading into today's session. A number of Apricus Biosciences Inc short sellers managed to dodge this bullet, however. In the most recent reporting period, short interest plunged 35.7%.

• JAZZ has jumped 10.4% to $127.56, after the U.S. Food and Drug Administration (FDA) granted the company's petition to not approve generic versions of its narcolepsy treatment Xyrem, without including a notice about potential drug interactions. This is a coup for Jazz Pharmaceuticals plc, which watched the FDA yesterday approve a Xyrem generic developed by Roxane Laboratories. SunTrust Robinson said the labeling decision "strengthens Jazz's position in settlement talks with generics makers." Due to the gap, the stock is now in modestly positive year-over-year territory. On Wall Street, hopes are extremely high within the brokerage community. Eleven analysts rate JAZZ a "strong buy," compared to one "hold" and not a single "sell."

• CCJ is on the short-sale restricted list, as it's plummeted more than 18% to trade at $10.84 -- putting the shares on track for their worst day in six years. Weighing heavily on the stock is Cameco Corp's woeful 2016 forecast, as well as its 10% workforce reduction announcement -- not to mention a downgrade to "market perform" at BMO Capital. On the charts, the shares are now testing their 320-day moving average, which they'd only recently broken through. A number of short sellers are counting on CCJ to breach this key trendline and extend its run lower. Over the last two reporting periods, short interest on the stock jumped by 27.8%, and it would currently take over a week to cover all the shorted shares, at the equity's average daily trading volume.